Chronic Plaque Psoriasis - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
106 Pages - GMD12043
$2,000.00

Summary

Global Markets Direct’s, ‘Chronic Plaque Psoriasis - Pipeline Review, H1 2014’, provides an overview of the Chronic Plaque Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Plaque Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Plaque Psoriasis - Overview 9
Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis 10
Chronic Plaque Psoriasis - Therapeutics under Development by Companies 11
Chronic Plaque Psoriasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Chronic Plaque Psoriasis - Products under Development by Companies 16
Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development 18
Boehringer Ingelheim GmbH 18
Eli Lilly and Company 19
GlaxoSmithKline plc 20
Biotest AG 21
Merck & Co., Inc. 22
AbGenomics International, Inc. 23
ApoPharma Inc. 24
Novartis AG 25
Actelion Ltd 26
Pfizer Inc. 27
Sandoz Inc. 28
Incyte Corporation 29
OPKO Health, Inc. 30
Can-Fite BioPharma Ltd. 31
Almirall, S.A. 32
AbbVie Inc. 33
Chronic Plaque Psoriasis - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ixekizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
adalimumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CF-101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tildrakizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LAS-41008 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
etanercept biosimilar - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
etanercept biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
adalimumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
baricitinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
tregalizumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ponesimod - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AbGn-168H - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
lunacalcipol - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GSK-2586184 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
orilotimod - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BI-655066 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
INCB-39110 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
CJM-112 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PF-06263276 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Chronic Plaque Psoriasis - Recent Pipeline Updates 72
Chronic Plaque Psoriasis - Dormant Projects 94
Chronic Plaque Psoriasis - Discontinued Products 95
Chronic Plaque Psoriasis - Product Development Milestones 96
Featured News & Press Releases 96
Mar 22, 2014: Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 96
Dec 09, 2013: Coronado Biosciences Announces IND Submission for TSO for the Treatment of Moderate to Severe Chronic Plaque Psoriasis 97
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 98
Jan 09, 2012: Biocon Announces Positive Efficacy Data With Itolizumab In Pivotal Psoriasis Study 99
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 100
May 25, 2011: Centocor's New Stelara Data Shows Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis 101
Apr 15, 2011: Merck and Johnson & Johnson Reach Agreement on Distribution Rights for Remicade and Simponi 102
Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA 103
Sep 14, 2010: Biotie's Phase I Trial With BTT-1023 Demonstrates Safety Profile 103
Sep 02, 2010: Avesthagen Obtains Indian Patent For AVENT 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Chronic Plaque Psoriasis, H1 2014 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Development by Companies, H1 2014 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Development by Companies, H1 2014 (Contd..1) 17
Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2014 18
Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H1 2014 19
Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2014 20
Chronic Plaque Psoriasis - Pipeline by Biotest AG, H1 2014 21
Chronic Plaque Psoriasis - Pipeline by Merck & Co., Inc., H1 2014 22
Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H1 2014 23
Chronic Plaque Psoriasis - Pipeline by ApoPharma Inc., H1 2014 24
Chronic Plaque Psoriasis - Pipeline by Novartis AG., H1 2014 25
Chronic Plaque Psoriasis - Pipeline by Actelion Ltd, H1 2014 26
Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H1 2014 27
Chronic Plaque Psoriasis - Pipeline by Sandoz Inc., H1 2014 28
Chronic Plaque Psoriasis - Pipeline by Incyte Corporation, H1 2014 29
Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H1 2014 30
Chronic Plaque Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 31
Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H1 2014 32
Chronic Plaque Psoriasis - Pipeline by AbbVie Inc., H1 2014 33
Assessment by Monotherapy Products, H1 2014 34
Number of Products by Stage and Target, H1 2014 37
Number of Products by Stage and Mechanism of Action, H1 2014 40
Number of Products by Stage and Route of Administration, H1 2014 42
Number of Products by Stage and Molecule Type, H1 2014 44
Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H1 2014 72
Chronic Plaque Psoriasis - Dormant Projects, H1 2014 94
Chronic Plaque Psoriasis - Discontinued Products, H1 2014 95

List of Figures
Number of Products under Development for Chronic Plaque Psoriasis, H1 2014 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 15
Assessment by Monotherapy Products, H1 2014 34
Number of Products by Top 10 Target, H1 2014 35
Number of Products by Stage and Top 10 Target, H1 2014 36
Number of Products by Top 10 Mechanism of Action, H1 2014 38
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 39
Number of Products by Top 10 Route of Administration, H1 2014 41
Number of Products by Stage and Top 10 Route of Administration, H1 2014 42
Number of Products by Top 10 Molecule Type, H1 2014 43
Number of Products by Stage and Top 10 Molecule Type, H1 2014 44

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax